Keratinocyte Stem Cell Differentiation Protocol
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) into epidermal keratinocytes fail to generate engraftable keratinocyte stem cells with long-term proliferative capacity and high purity, limiting their application in transplantation therapies and drug development.
Innovation Solution
A method involving the differentiation of pluripotent stem cells into engraftable keratinocyte stem cells through a multi-step process, including forming aggregates in suspension culture with retinoic acid and BMP4, followed by culture in specific media containing cholera toxin and TGFβR1 kinase inhibitor to achieve keratinocyte progenitors, and finally maturation into engraftable stem cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional differentiation methods using retinoic acid and BMP4 are used, then keratinocyte differentiation is achieved, but the cells lack long-term proliferative capacity and engraftability
Solution Approach 1:
The differentiation process is divided into distinct sequential stages: initiation phase (retinoic acid and BMP4 treatment), progenitor phase (EGF and bFGF treatment), and maturation phase (maintenance in keratinocyte medium). This segmentation allows each stage to optimize for its specific function, with the maturation phase specifically designed to restore stem cell properties and long-term proliferative capacity while maintaining engraftability
Solution Approach 2:
The initiation phase using retinoic acid and BMP4 performs preliminary differentiation to establish keratinocyte lineage commitment before subsequent phases. This preliminary action prepares the cells for proper maturation and ensures they are primed to acquire stem cell characteristics in the later phases, rather than attempting direct differentiation to final stem cells
2Manufacturing precision
If conventional differentiation procedures are used, then some keratinocyte differentiation occurs, but high purity keratinocyte stem cells cannot be obtained
Solution Approach 1:
The protocol incorporates marker-based monitoring (cytokeratin 14, cytokeratin 15, CD34) at each phase to assess differentiation progress and stem cell marker expression. This feedback allows optimization of treatment duration and conditions to maximize the proportion of cells achieving the desired keratinocyte stem cell state with high purity and engraftability
Solution Approach 2:
The protocol systematically changes culture parameters including growth factor concentrations (EGF, bFGF), treatment durations (5 days initiation, 7 days progenitor, 7 days maturation), and medium compositions at each phase. These parameter changes are optimized to progressively enrich for keratinocyte stem cells with high purity while maintaining productivity
3Duration of action of stationary object
If existing differentiation methods are applied, then epidermal keratinocytes are generated, but they cannot be maintained in culture for extended periods
Solution Approach 1:
The maturation phase maintains cells in an undifferentiated stem cell state through continuous exposure to optimal culture conditions including EGF, bFGF, and other growth factors. This continuous maintenance prevents differentiation and senescence, allowing cells to be cultured for extended periods while preserving their functional capacity for engraftment and differentiation when needed
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
Provided herein are methods for the generation of functional keratinocyte stem cells that are differentiated directly from human ESCs/iPSCs in a chemically defined serum-free cell culture system, as well as cells derived therefrom and methods of use thereof. Also provided are methods for culturing primary keratinocytes.